Salesforce upgraded, Adobe downgraded: Wall Street's top analyst calls
BofA upgraded Salesforce (CRM) to Buy with a $285 target, citing enterprise platform resilience. Raymond James upgraded Humana (HUM) to Outperform with a $520 target, noting Medicare Advantage growth. T-Mobile (TMUS) also upgraded to Outperform with a $170 target. Truist upgraded First Solar (FSLR) to Buy with a $270 target. JPMorgan upgraded Biogen (BIIB) to Overweight with a $300 target. Wells Fargo double-downgraded Adobe (ADBE) to Underweight with a $225 target.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the immediate sentiment and positioning shift from rating changes, with some names flagged as heading into near-term earnings (e.g., T-Mobile ahead of Q3).
Market read
Rating changes with explicit price-target revisions can drive short-term relative moves, especially where the article highlights earnings timing or growth durability concerns.
What to watch
Several rationales are qualitative (AI disintermediation, catalyst path, timing) and lack quantified drivers in the article, increasing the risk that the market overreacts to rating headlines.
Background
The piece is a multi-name Wall Street analyst actions roundup, featuring upgrades, downgrades, and new coverage with price targets and thesis notes.
Ticker impact
BofA upgraded Salesforce to Buy from Underperform and lifted its price target to $285, citing reduced AI disintermediation risk for large enterprises.
Likely upward pressure as the market digests the upgrade and the revised AI disintermediation thesis.
The article provides a clear rating change plus a materially higher price target and a specific thesis tied to enterprise platform stickiness.
Raymond James upgraded Humana to Outperform, pointing to 4-star-plus Medicare Advantage membership rising to 95% for 2027 from 41% in 2026.
Likely positive drift as the market focuses on the quantified membership shift and EPS estimate lift.
The article includes specific membership and EPS contribution details, but it is still an analyst note rather than a company disclosure.
Raymond James upgraded T-Mobile to Outperform with a $170 target, arguing fears about competition from SpaceX are overblown ahead of Q3 results.
Likely upward pressure into Q3 as traders price in reduced competitive downside.
The catalyst is upcoming results, but the competitive claim is analyst-driven and not a new company fact.
Truist upgraded First Solar to Buy and raised its price target to $270, citing a stronger pricing backdrop into the 2030s.
Likely positive bias as investors adjust expectations for pricing durability.
The article provides a clear target increase and a specific pricing-duration thesis, but it remains a sell-side view.
JPMorgan upgraded Biogen to Overweight and increased its price target to $300, citing an increasingly compelling catalyst path and improved long-term growth outlook.
Likely upward pressure as the market re-evaluates the catalyst path narrative.
The article states the thesis but does not specify the catalysts, limiting conviction.
Wells Fargo double downgraded Adobe to Underweight from Equal Weight and cut its price target to $225, saying Q3 results were muted and cracks are emerging.
Likely downward pressure as investors reassess Adobe’s growth profile and risk of further estimate cuts.
The article includes a clear double downgrade plus a substantial target reduction and a concrete interpretation of Q3 results.
Phillip Securities downgraded Microsoft to Neutral from Accumulate and set a $515 price target after adjusting ratings in the software space.
Likely mild downside or reduced upside as the market absorbs the downgrade.
The article provides the rating change and target, but the rationale is broad (software re-rating) rather than Microsoft-specific fundamentals.
Barclays downgraded HubSpot to Equal Weight from Overweight, keeping a $240 target, and said timing will take longer than expected.
Likely modest negative bias as investors focus on slower-than-expected monetization timing.
The thesis is specific (timing), but the article does not quantify the delay.
Market effects
Broad software and healthcare coverage changes can shift relative performance within those sectors, especially around AI and growth durability narratives.
Primarily US-listed large-cap and mid-cap sentiment; limited direct cross-region impact implied.
Energy transition and brokerage-platform narratives may influence broader global thematic positioning, but the article is mostly single-name analyst actions.
Counterpoint
Analyst upgrades and downgrades may reflect positioning and model recalibrations rather than new company fundamentals, so price reactions could fade if upcoming earnings do not confirm the thesis.
Key entities
- companySalesforce
Upgraded by BofA to Buy from Underperform with a higher price target, citing reduced AI disintermediation risk.
- companyAdobe
Double downgraded by Wells Fargo to Underweight with a lower price target, citing muted Q3 and emerging growth cracks.
- companyHumana
Upgraded by Raymond James, highlighting a large improvement in 4-star-plus Medicare Advantage membership mix.
